

# ANTIANGINAL DRUGS

## LEARNING OUTCOMES

Recognize variables contributing to a balanced myocardial supply versus demand

Expand on the drugs used to alleviate acute anginal attacks versus those meant for prophylaxis & improvement of survival

Detail the pharmacology of nitrates, other vasodilators, and other drugs used as antianginal therapy



# Calcium channel blockers

## Classification

## Selectivity

Dihydropyridines:-

Nifedipine ,

Nifedipine, Nisoldipine, Amlodipine

Vascular smooth muscle

Verapamil

es:-

Cardiomyocytes


Diltiazem

:-

Intermediate

# Mechanism of Action

Binding of calcium channel blockers [CCBs] to the L-type Ca channels ↓ their frequency of opening





## Antianginal Action

↓ **Cardiomyocyte Contraction** → ↓ cardiac work through their –ve inotropic & chronotropic action (verapamil & diltiazem) → **↓ myocardial oxygen demand**

↓ **VSMC Contraction** → ↓ After load → ↓ cardiac work → **↓ myocardial oxygen demand**

Coronary dilatation → **↑ myocardial oxygen supply**

## Therapeutic Uses

### IN VARIANT ANGINA

Short acting dihydropyridine should be avoided ??

▶ Attacks prevented (> 60%) /  
sometimes variably aborted

Can be combined to  $\beta$ -AR blockers???

### IN UNSTABLE ANGINA:

Can be combined with nitrates???


Seldom added in refractory cases

Dihydropyridenes useful antianginal if with CHF??

# Beta Adrenoceptor Blockers

Examples Atenolol, Bisoprolol, Metoprolol ( $\beta_1$  - Selective)

## Antianginal Mechanism



# Beta Adrenoceptor Blockers

**Indications in angina**

**In stable angina**

**Regular prophylaxis, selective are preferred?**

**First choice for chronic use?**

**Can be combined with nitrates?**

**Can be combined with dihydropyridine CCB?**

**Verapamil?**

**In variant angina**

**Contraindicated?**



# Beta Adrenoceptor Blockers

## Indications in angina

**In Unstable angina**

**Halts progression to MI, improve survival**

**In Myocardial infarction**

**Reduce infarct size**

**Reduce morbidity & mortality**

→ reduce **O<sub>2</sub> demand**

→ reduce **arrhythmias**



# **Beta Adrenoceptor Blockers**

**$\beta$ - blockers should be withdrawn gradually?**

**Given to diabetics with ischemic heart disease?**

## MINICASE



Which antianginal drug is the best choice for the case of Helmi? And Why?

## MINICASE



If Helmi does not respond to monotherapy, what other drug should be added to his regimen?




# Potassium channel openers

**Nicorandil**

**Mechanism**

Activation of ATP-sensitive K<sup>+</sup> channels

- Dilation of coronary resistance arterioles




Nitrate-associated effects

- Vasodilation of coronary epicardial arteries

It has dual mechanism of action;

1. Opens K<sub>ATP</sub> channels (> arteriolar dilator)
2. NO donor as it has a nitrate moiety (> venular dilator)



# Pharmacodynamic Effects

**As K channel opener**

**As nitric oxide donor** → opening of K channels

→ hyperpolarization → vasodilatation

**NO ↑ cGMP/PKG → vasodilatation**

**On cardiomyocytes opening of K channels → repolarization**

→ ↓ cardiac work

## **Indications**

**Prophylactic 2nd line therapy in stable angina & refractory variant angina**

## **ADRs**

**Flushing, headache,  
Hypotension, palpitation, weakness  
Mouth & peri-anal ulcers, nausea and vomiting.**



## THINK-PAIR-SHARE

A 55-year-old woman complained to her physician of palpitations, flushing of the face, and vertigo. The woman, suffering from diabetes mellitus, was giving herself three daily doses of insulin. She had been recently diagnosed with exertional angina for which nitrate therapy was started with transdermal nitroglycerin and oral isosorbide mononitrate. After 3 weeks of therapy, her anginal attacks were less frequent but not completely prevented. Which would be an appropriate next therapeutic step for this patient?

# Metabolically Acting Agents


e.g. Trimetazidine

O<sub>2</sub> requirement of glucose pathway is

low

During  
blun

is rise,



Reduces O<sub>2</sub> demand without altering hemodynamics

# Trimetazidine

Indications

Used as an add on therapy

ADRs

GIT disturbances

Contraindications

Hypersensitivity reaction

Pregnancy & lactation




# Metabolically Acting Agents

## Ranolazine

Inhibits the late sodium current which increases during ischemia

It prolongs  
Class Ia & II

Toxicity develops as;  
*diltiazem*  
*antibiotics,*



n;

inhibitors

ADRs:- dizziness , constipation

Used in chronic angina concomitantly with other drugs

## MINICASE



Which antihyperlipidemic drug should be prescribed to Helmi?

# Ivabradine

Ivabradine Selectively blocks  $I_f$



Ivabradine reduces slope of depolarization, slowing HR, reducing myocardial work & O<sub>2</sub> demand

## Ivabradine

Used in combination with beta blockers in heart failure with LVEF lower than 35% inadequately controlled by beta blockers whose heart rate exceeds 70/min

ADR:- luminous phenomena

$I_f$  current is a pacemaker



## Agents that improve prognosis

- Aspirin / other antiplatelet agents
- ACE inhibitors
- Statins
- $\beta$ -blockers

Halt progression  
Prevent acute insult  
Improve survival



# MEMORY MATRIX

In the following table indicate increase, decrease or no effect with signs  $\uparrow$ ,  $\downarrow$ ,  $-$  respectively

Drug/Class	HR	BP	Wall Tension	Contractility	O <sub>2</sub> Supply
Beta-blockers					
CCBs					
Verap/Dilt					
Dihydropyridines					
Nitrates					
Ranolazine					